Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 4 clients • 10 examiners • 10 art units • 0 of 10 (0%) have an AI response strategy ready
White & Case LLP is active in Biotechnology & Pharmaceuticals, with 2805 career applications and 10 pending office actions. The profile therefore combines a broad application base with a limited group of currently pending examination matters. Its resolved allowance rate is 81.0%, indicating that allowance was recorded for a majority of resolved applications.
Allowances average 2.65 office actions. This suggests that examination commonly includes multiple actions before allowance, even though the average is below three actions. For practitioners, the allowance rate supplies an outcome measure, while the action average describes prosecution activity associated with that outcome. The pending-action figure should be considered separately when evaluating current docket needs.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (20%) |
| §112 only | 1 (10%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 4 (40%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, SIN J | 1 | 68.8% | +25.1% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 26d |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | RYAN, DOUGLAS CHARLES | 60d overdue |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 26d |
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | LEE, SIN J | — |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | — |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | — |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | PATEL, SAGAR S | — |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Acceleron Pharma | 5 |
| Xylonix Pte. Ltd. | 2 |
| Disc Medicine | 2 |
| Encoded Therapeutics | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1674 | 1 |
| 1641 | 1 |
| 1647 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1618 | 1 |
| 1654 | 1 |
| 1658 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | Xylonix Pte. Ltd. | LEE, SIN J | 1613 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | Acceleron Pharma, Inc. | CHANDRA, GYAN | 1674 | DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | Acceleron Pharma, Inc. | SZPERKA, MICHAEL EDWARD | 1641 | §102§103DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Disc Medicine, Inc. | NOLAN, JASON MICHAEL | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. | PATEL, SAGAR S | 1626 | §103§112DPOther | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18282094 | PHARMACEUTICAL POLYMER CONJUGATES | Xylonix Pte. Ltd. | BAEK, JONGHWAN NMN | 1618 | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | Acceleron Pharma, Inc. | FISCHER, JOSEPH | 1658 | §102§103§112Other | Non-Final OA | 26d | Pending | May 04, 2023 |
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | Encoded Therapeutics, Inc. | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 60d overdue | Pending | Sep 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial81.0% of resolved applications prosecuted by White & Case LLP were allowed, across 2,805 applications in USPTO records.
2.65 office actions per allowed application on average.
10 pending office actions as of October 2026, for 4 clients, before 10 examiners in 10 art units.
